US Material Events SEC 8-K Filings — March 30, 2026

30-03-2026

Ingevity Corporation, along with Ingevity Holdings SRL and Ingevity UK Ltd, entered into a Second Amendment and Restatement Agreement dated March 26, 2026, amending their existing credit agreement to establish new Revolving Commitments totaling $750 million, with proceeds used to repay all outstanding revolving loans under the prior facility. The transaction involves JPMorgan Chase Bank, N.A. as Administrative Agent and other lenders, with effectiveness subject to standard conditions including legal opinions, solvency certificates, and repayment of prior obligations. No comparative financial metrics or performance declines are disclosed in the filing.

• ·Existing Credit Agreement originally dated June 23, 2022
• ·Amendment Arrangers: JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citizens Bank, N.A., PNC Bank, National Association, TD Securities (USA) LLC
• ·Legal opinions required from Wachtell, Lipton, Rosen & Katz, McGuireWoods LLP, Loyens & Loeff CVBA, NautaDutilh BV/SRL, Cahill Gordon & Reindel (UK) LLP
• ·Engagement Letter dated February 19, 2026

30-03-2026

On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors of Cartesian Therapeutics, Inc., notified the company of his intent to resign effective March 31, 2026, to pursue other opportunities. Dr. Kalayoglu served as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee since 2023. His resignation was not due to any disagreement with the company’s operations, policies, or practices.

• ·The report was signed by Carsten Brunn, Ph.D. on March 30, 2026.
• ·Cartesian Therapeutics, Inc. is incorporated in Delaware, with CIK 0001453687 and IRS Employer Identification No. 26-1622110.

30-03-2026

HealthEquity, Inc. (NASDAQ: HQY) appointed William ‘Bill’ Gassen, president and CEO of Sanford Health, to its board of directors effective March 26, 2026, expanding the board to 10 directors with eight independent. Gassen will serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee, bringing expertise in healthcare delivery and financing. The company administers HSAs and other consumer-directed benefits for more than 17 million accounts.

• ·Gassen has served as Sanford Health CEO since November 2020, leading the nation’s largest rural health system.
• ·Prior roles at Sanford Health: chief administrative officer (Jan-Nov 2020), chief human resources officer (Jul 2016-Jan 2020), vice president of human resources integration and corporate services (Oct 2014-Jun 2016), corporate counsel (Feb 2012-Sep 2014).
• ·Gassen holds a bachelor’s degree in criminal justice and J.D. from the University of South Dakota.

30-03-2026

OnKure Therapeutics entered into a securities purchase agreement on March 27, 2026, for a private placement expected to generate approximately $150.0 million in gross proceeds through the sale of 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, with closing anticipated on March 31, 2026. The company elected Dr. Liam Ratcliffe, affiliated with lead investor AI Biotechnology LLC, as a Class I director effective upon closing, and plans to use proceeds for preclinical/clinical development of next-generation PI3Kα inhibitors OKI-345 and OKI-355, with IND submissions targeted for H1 2027. However, despite progress in the PIKture-01 trial (completed dose escalations with n=38 single-agent and n=33 + fulvestrant), the company will not pursue further independent clinical development of OKI-219.

• ·Private Placement closing subject to customary conditions on March 31, 2026.
• ·180-day lock-up for executives/directors and Company on share issuances post-Closing.
• ·Registration Statement to be filed within 30 days after Closing, with effectiveness targets of 90-120 days.
• ·Pre-Funded Warrants exercisable at $0.0001 per share, no expiration until fully exercised.
• ·Phase 2 dose evaluation in PIKture-01 (OKI-219 triplets) to complete in 2026; mature data presentation by year-end.
• ·Dr. Ratcliffe to receive standard non-employee director compensation per Company policy.

30-03-2026

Our Bond, Inc. (OBAI) entered into Amendment No. 2 to its Securities Purchase Agreement (Equity Line SPA) with Ascent Partners Fund LLC on March 29, 2026, amending terms for Regular Closings (max $1,000,000 or 100% of average daily traded value over prior 10 trading days) and Expanded Closings (up to $5,000,000 under specific volume and price conditions or if average daily traded value exceeds $4,000,000). The amendment allows advance notices anytime during trading days, multiple per day, and includes extended hours trading in key definitions. No financial performance metrics or period comparisons are reported.

• ·Expanded Closing advance notice requires trading volume exceeding 3 times the average daily volume over the prior 10 trading days.
• ·VWAP, daily traded value, and volume definitions now include extended hours trading.
• ·Equity Line SPA effective date clarified as the registration statement effective date for Ascent’s resale of shares.

30-03-2026

Amphenol Corporation entered into an Indenture dated March 30, 2026, with Amphenol Technologies Holding GmbH as issuer, Amphenol Corporation as guarantor, and U.S. Bank Trust Company, National Association as trustee, for the issuance of Notes. This agreement creates a direct financial obligation under Item 2.03. The filing incorporates an Officers’ Certificate establishing the Notes and lists various exhibits including legal opinions.

• ·Exhibits include: 4.1 (Indenture), 4.2 (Officers’ Certificate), 4.3 (Form of Global Note), 5.1 (Opinion of Latham & Watkins LLP, New York), 5.2 (Opinion of Latham & Watkins LLP, Frankfurt), 23.1 and 23.2 (Consents), 104 (XBRL Cover Page)
• ·Incorporated by reference into Registration Statement No. 333-293923

30-03-2026

Volato Group, Inc. entered into an ATM Sales Agreement with Curvature Securities, LLC to offer and sell up to $3,700,000 of Class A Common Stock at-the-market. The company provided an update on its pending merger with M2i Global, Inc., where M2i shareholders are expected to receive approximately 85% ownership of the combined company (via ~119.2M shares), resulting in significant dilution for existing Volato shareholders who will hold ~15%. The merger faces risks including stockholder approvals, integration challenges, operational disruptions, and potential failure to realize strategic benefits.

• ·ATM sales made via methods permitted under Rule 415, including directly on NYSE American LLC.
• ·Merger Agreement originally dated July 28, 2025; shelf registration on Form S-3 (File No. 333-290219) effective September 30, 2025.
• ·Company plans to seek stockholder approval for potential reverse stock split to meet NYSE American listing requirements.
• ·Merger closing subject to M2i Global and Volato stockholder approvals, with risks of delays, termination, or adverse business impacts.

30-03-2026

Nexstar Media Group, Inc. and Nexstar Media Inc. entered into Amendment No. 9 to their Credit Agreement dated March 25, 2026, effective on the same date, under which Bank of America, N.A., as Term B-7 Lender, provides new Term B-7 Loans in an aggregate principal amount of $1,750,000,000. The proceeds are used to fully repay outstanding Term B-6 Loans (Term B-6 Refinancing) and pay fees and expenses associated with the transaction. The amendment includes standard conditions precedent, representations, and reaffirmations of loan documents, with no reported changes in financial performance metrics.

• ·Amendment executed by Borrower (Nexstar Media Inc.), Nexstar Media Group, Inc., other Loan Parties, Administrative Agent (Bank of America, N.A.), and Term B-7 Lender.
• ·Ninth Amendment Effective Date: March 25, 2026.
• ·SEC 8-K filing date: March 30, 2026, covering Items 1.01, 1.02, 2.03, 9.01.

30-03-2026

AB Private Credit Investors Corp and multiple affiliated Borrowers and General Partners entered into the Eighteenth Amendment to their Revolving Credit Agreement originally dated June 14, 2019, with HSBC Bank USA, National Association as Administrative Agent, effective as of March 23, 2026. The amendment modifies certain sections and schedules of the Credit Agreement as set forth in Annex A (not provided), subject to conditions including execution, beneficial ownership certifications, and payment of fees. All parties reaffirmed the validity of liens, resolutions, and obligations under the Loan Documents, with representations that no Potential Default or Event of Default exists.

• ·Original Revolving Credit Agreement dated June 14, 2019.
• ·This is the eighteenth amendment; prior amendments listed from December 23, 2020 through December 8, 2025.
• ·Governing law: State of New York.
• ·SEC Filing Date: March 30, 2026; Items: 1.01, 2.03, 9.01.

30-03-2026

Ensysce Biosciences, Inc. announced the resignation of Board Director Lee Rauch effective March 24, 2026, who chaired the Nominating and Corporate Governance Committee and served on the Audit and Compensation Committees, citing disagreements with Board actions including the approval of retention and severance packages. The Board approved three-month severance packages for three managers and extended CFO Mr. Humphrey's retention package from 6 to 9 months, totaling approximately $205,475, to preserve enterprise value amid strategic alternatives review. Ms. Rauch voted against the packages on March 23, 2026, highlighting internal discord.

• ·Resignation notice attached as Exhibit 17.
• ·Board approval of packages on March 27, 2026.

30-03-2026

On March 24, 2026, Noodles & Company Class I directors Robert Hartnett and Mary Egan notified the Board they will not stand for re-election at the 2026 Annual Meeting of Stockholders, continuing to serve until then with no disagreements with management or the Board. The Board voted to reduce its size from nine to seven members effective at the Annual Meeting to better align with company size and complexity, and nominated Mr. Lynch as a Class I director contingent on his election and resignation from Class III to rebalance board classes.

• ·Directors Hartnett and Egan's decisions to not stand for re-election were not due to any disagreement with management, Board, operations, policies, or practices.
• ·Annual Meeting date not specified; board changes effective upon its conclusion.

30-03-2026

On March 25, 2026, QuoteLab, LLC and QL Holdings LLC, subsidiaries of MediaAlpha, Inc., entered into an Amendment and Restatement Agreement amending their existing Credit Agreement, establishing a new $150 million five-year senior secured term loan facility to refinance prior term loans and support general corporate purposes, and a new $60 million five-year senior secured revolving credit facility. The facilities are guaranteed by Holdings and secured by substantially all assets of Holdings and the Borrower, with maturity on March 25, 2031, and term loan amortization beginning June 30, 2026. No performance declines or flat metrics are reported in this financing update.

• ·Borrowings bear interest at Term SOFR, Daily Simple SOFR, or Alternate Base Rate plus applicable margins based on consolidated total net leverage ratio.
• ·Term loans require prepayments from non-ordinary course asset sales, casualty, and condemnation events, subject to exceptions.
• ·Credit Agreement includes customary affirmative, negative, and financial covenants and default provisions.

30-03-2026

Leidos Holdings, Inc. (NYSE: LDOS) completed its approximately $2.4 billion acquisition of ENTRUST Solutions Group from Kohlberg on March 30, 2026, effectively doubling its presence in the energy infrastructure market and adding more than 3,100 professionals with expertise in electric grid and natural gas infrastructure. The deal expands Leidos' engineering capabilities across power delivery and broadens its utility customer base, supporting the NorthStar 2030 strategy amid rising power demand. Leidos, with 47,000 global employees, reported approximately $17.2 billion in annual revenues for the fiscal year ended January 2, 2026.

• ·ENTRUST operates across 40+ locations in North America
• ·Leidos headquartered in Reston, Virginia

30-03-2026

NaturalShrimp Inc (SHMP) filed an 8-K on March 30, 2026, under Items 1.01 (Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.01 (Changes in Control), 5.02 (Director/Officer Changes), and 9.01 (Financial Statements and Exhibits), indicating significant corporate governance and control shifts. The filing attaches Exhibit 3.1, likely an amendment to the Articles of Incorporation or Bylaws. No financial metrics or performance data were disclosed.

• ·Filing includes Items: 1.01, 3.02, 5.01, 5.02, 9.01
• ·Exhibit 3.1 attached (likely governance amendment)

30-03-2026

On March 30, 2026, Addentax Group Corp. completed the acquisition of 34,200,000 shares of common stock in Keemo Fashion Group Limited from Guang Wen Global Group Limited for approximately $5.5 million, satisfied through the transfer of a portion of an existing bond. Following the transaction, the Company holds approximately 62.18% of the voting rights on a fully diluted basis, making Keemo Fashion a controlled subsidiary. No negative financial impacts or performance declines are disclosed.

• ·Stock Purchase Agreement originally dated February 17, 2026, previously disclosed in 8-K filings on February 19, 2026 and 8-K/A on March 16, 2026
• ·Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document)

30-03-2026

Connect Biopharma announced positive topline results from its Phase 1 study (CBP-201-105) of intravenous rademikibart (300 mg, 2-minute IV push) in asthma and COPD patients, showing rapid FEV1 improvements of ≥200 mL in many patients as early as 15 minutes post-dosing, with mean improvements of ~200-400 mL maintained through Day 29 versus placebo decline. The treatment was generally well-tolerated with no serious adverse events, no severe AEs, and no discontinuations. Ongoing Phase 2 Seabreeze STAT studies expect topline data in mid-2026.

• ·Mean baseline FEV1: 1.9 L (asthma), 1.55 L (COPD)
• ·Randomized 4:1 rademikibart:placebo
• ·Exclusive license to Simcere for rademikibart in Greater China with royalties up to low double-digits
• ·Conference call and webcast on March 30, 2026 at 8:00 a.m. ET

30-03-2026

Spire Inc. announced the sale of its gas marketing business, Spire Marketing Inc., to Boardwalk Pipelines, LP for $215 million in cash, expected to close in Q3 FY2026, to sharpen focus on regulated utility operations, improve risk profile, and fund the Piedmont Natural Gas Tennessee acquisition and corporate purposes. The company reaffirmed FY2026 adjusted EPS guidance of $5.25–$5.45 and long-term EPS growth of 5-7% from the original FY2027 midpoint of $5.75. However, updated FY2027 adjusted EPS guidance was lowered to $5.40–$5.60 from the prior $5.65–$5.85.

• ·Transaction subject to regulatory approvals, customary closing conditions, and HSR Antitrust waiting period.
• ·FY2026 adjusted EPS guidance of $5.25–$5.45 affirmed, reflecting full-year earnings from Spire Marketing and storage prior to sales.
• ·Piedmont Natural Gas Tennessee acquisition expected to close in Q1 calendar 2026.
• ·Update on potential sale of natural gas storage facilities expected by Q2 FY2026 earnings call in May 2026.

30-03-2026

Capstone Green Energy Holdings, Inc. (CGEH) announced a $112.5 million strategic investment led by Monarch Alternative Capital LP, consisting of $80 million in new senior convertible preferred stock and $15 million in common stock from Monarch, plus a $17.5 million PIPE from existing investors. $85 million of proceeds will redeem legacy preferred equity held by a Goldman Sachs affiliate, simplifying the capital structure and making Capstone Green Energy LLC a wholly owned subsidiary. Remaining funds support general working capital and growth initiatives, including AI data center expansion, with board expansion to seven members including two Monarch appointees and a path to national exchange listing.

• ·Preferred Stock convertible at $5.00 per share, 5.00% PIK dividend, senior ranking, mandatory conversion if stock trades above $15.00 for 20 of 30 days.
• ·PIPE priced at $4.50 per share.
• ·45-day lock-up for Company directors and executives.
• ·Resale registration statement to be filed within 30 days of closing.
• ·Initial listing application for national exchange within 12 months.
• ·Expected closing on or about March 31, 2026.

30-03-2026

Douglas G. Thompson resigned as CEO and Managing Director effective March 31, 2026, to pursue new opportunities, leading the Board to reduce its size from seven to six members. Garold Spindler, age 78 and current Executive Chair with extensive coal industry experience, was appointed Interim CEO effective April 1, 2026, under a new employment agreement with an annual base salary of $1,250,000. Additionally, Greg Pritchard was appointed Board Chair effective the same date.

• ·Mr. Thompson informed of resignation on February 22, 2026 (February 23 in Australia).
• ·Mr. Spindler previously served as CEO from August 2018 to May 2023.
• ·Employment agreement dated March 27, 2026; terminable with 30 days' notice; includes 1-year non-compete.
• ·No family relationships or related party transactions with Mr. Spindler.

30-03-2026

Atmos Energy Corporation extended the maturity of its $1.5 billion senior unsecured Three Year Credit Facility by one year to March 28, 2029, and its $1.5 billion senior unsecured Five Year Credit Facility by one year to March 28, 2031, both effective as of March 27, 2026. These extensions, made pursuant to Section 2.23 of each Revolving Credit Agreement originally entered on March 28, 2024, maintain the company's total revolving credit capacity at $3.0 billion without other reported changes.

• ·Extensions allow for up to two one-year extensions total per facility
• ·Facilities administered by Crédit Agricole as Administrative Agent

30-03-2026

Kirby Corporation entered into an Amended and Restated Credit Agreement on March 26, 2026, amending and restating its prior credit agreement dated July 29, 2022, with JPMorgan Chase Bank, N.A. as administrative agent and a syndicate of lenders including Bank of America, N.A., PNC Bank, National Association, Wells Fargo Bank, National Association as syndication agents, and BOKF, N.A. dba Bank of Texas as documentation agent. The agreement governs revolving loans, swingline loans, and letters of credit, with applicable margins for interest rates and fees determined by the company's S&P, Moody's, and/or Fitch ratings, ranging from 0.00%-0.500% over ABR and 0.875%-1.500% over Term SOFR/RFR, plus commitment fees of 0.070%-0.200%. No borrowings or specific facility size are detailed in the filing.

• ·Prior agreement dated July 29, 2022
• ·Pricing levels based on S&P/Moody’s/Fitch ratings (Levels I to V: A-/A3/A- or better to BB+/Ba1/BB+ or worse)
• ·Schedules include Commitments (2.01), Existing Letters of Credit (1.01), Consolidated Subsidiaries (3.01)

30-03-2026

Ares Commercial Real Estate Corp (ACRE), as guarantor, along with its subsidiaries ACRC Lender MS LLC and ACRC Lender MS II LLC as sellers, entered into the Eighth Amendment to the Master Repurchase and Securities Contract with Morgan Stanley Bank, N.A. as buyer, dated March 24, 2026. The amendment sets the Facility Amount at $350,000,000, establishes a Preapproved Accordion Amount of $400,000,000 with provisions for further increases subject to conditions, and extends the Initial Facility Termination Date to July 16, 2029. Seller paid an Upsize Fee of $78,082.19, with representations confirming no existing Defaults, Events of Default, or Material Adverse Effects.

• ·Original Repurchase Agreement dated January 16, 2020, with Seller II joinder via Omnibus Amendment dated December 23, 2024.
• ·Effectiveness conditions include executed amendment, payment of Buyer's costs and expenses, Officer's Certificate, good standing certificates, and legal opinions within 10 Business Days.

30-03-2026

Lunai Bioworks, Inc. (NASDAQ: LNAI) executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group, SAS or its assignee. The deal is structured as Series B Convertible Preferred stock at a fixed $1.50 per share conversion price, subject to a 19.9% beneficial ownership limitation, with no variable pricing or reset provisions. This acquisition enhances Lunai’s CNS Alzheimer’s pipeline by enabling effective brain delivery of therapeutics and expands potential applications to broader CNS disorders.

• ·Transaction announced on March 26, 2026; SEC filing dated March 30, 2026
• ·Fixed conversion price of $1.50 per share with 19.9% beneficial ownership limitation
• ·Platform targets acetylcholinesterase modulation pathways for neurological diseases

30-03-2026

Liberty Energy Inc. (NYSE: LBRT) announced a proposed private offering of $450.0 million aggregate principal amount of convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional $50.0 million. Proceeds will fund capped call transactions to mitigate dilution upon conversion and general corporate purposes. The offering includes potential market impacts from hedging activities by counterparties, which could affect the Class A Common Stock price positively or negatively.

• ·Notes mature on March 1, 2032; interest payable semiannually starting September 1, 2026
• ·Conversion possible under certain conditions prior to December 1, 2031, thereafter at any time until maturity
• ·Liberty may redeem notes for cash on or after March 1, 2029, if stock price >=130% of conversion price
• ·Offering to qualified institutional buyers under Rule 144A; not registered under Securities Act

30-03-2026

Precision Optics Corporation, Inc. (NASDAQ: POCI) announced on March 26, 2026, the commencement of an underwritten public offering of shares of its common stock (or equivalents), subject to market conditions with no assurance on completion, size, or terms. Lucid Capital Markets is acting as the sole book-running manager. The offering is pursuant to a shelf registration statement on Form S-3 (File No. 333-280047), filed June 7, 2024, amended June 11, 2024, and effective June 14, 2024.

• ·SEC filing date: March 30, 2026
• ·8-K Items: 1.01, 3.02, 8.01, 9.01
• ·Company address: 22 East Broadway, Gardner, Massachusetts 01440-3338
• ·Shelf registration File No.: 333-280047

30-03-2026

Expedia Group, Inc. entered into a new Credit Agreement dated March 27, 2026, with JPMorgan Chase Bank, N.A. as Administrative Agent and various lenders, providing for revolving loans, borrowings in US Dollars and Alternative Currencies (Euro, Sterling, Canadian Dollars, Australian Dollars), and letters of credit. The agreement includes commitments detailed in Schedule 2.01 (not specified in excerpt), with pricing tiers based on credit ratings from S&P, Moody's, and Fitch, featuring commitment fees of 10.0-25.0 basis points and Term Benchmark/RFR spreads of 100.0-175.0 basis points. No performance declines or flat metrics are mentioned, as this is a financing arrangement rather than operational results.

• ·Filing Date: March 30, 2026
• ·Alternative LC Currencies include Singapore Dollars and others acceptable to Administrative Agent and Issuing Bank
• ·Leverage Ratio covenant in Section 6.06
• ·Schedules include Commitments (2.01), Existing Letters of Credit (2.05A), Existing Indebtedness (6.01), Existing Liens (6.02)

30-03-2026

Star Equity Holdings, Inc.'s wholly owned subsidiary, Alliance Drilling Tools, LLC, closed the sale of its Texas property in Midland for $1.14 million and Utah property in Vernal for $0.55 million on March 27, 2026, pursuant to purchase agreements dated December 16, 2025. Simultaneously, ADT entered into 20-year triple net leasebacks for both properties, guaranteed by the company, under which ADT remains responsible for all rent and operating expenses. This completes two of three previously announced sale-leaseback transactions, following the Wyoming property closing on February 27, 2026.

• ·Lease terms commence March 27, 2026, and end on the 20th anniversary, with options for four additional five-year periods.
• ·Original purchase and sale agreements dated December 16, 2025, filed as Exhibits to Form 8-K on December 17, 2025.
• ·Custom Capital assigned its purchase rights to Alliance Texas and Utah, LLC immediately prior to closings.
• ·Wyoming property sale closed February 27, 2026, as previously reported.

30-03-2026

On March 24, 2026, NexPoint Diversified Real Estate Trust, through its indirect subsidiary NXDT Hospitality Holdco, LLC, entered into a Membership Interest Purchase Agreement to sell 100% of the membership interests in NHT Bradenton, LLC (owner of the Bradenton Hampton Inn & Suites property) to OSL Bradenton Downtown, LLC for approximately $26.3 million in cash, with the transaction closing on the same date. The net proceeds will be used for short-term liquidity needs. The buyer is deemed an affiliate of the Company's adviser NexPoint Real Estate Advisors X, L.P., and the agreement was reviewed and approved by the Company's Audit Committee in compliance with its Related Party Transaction Policy.

• ·Transaction subject to customary closing adjustments.
• ·MIPA contains customary representations, warranties, and covenants.

30-03-2026

On March 30, 2026, Rocket Lab Corporation amended Sir Peter Beck's employment agreement, voluntarily reducing his annual base salary to $1.00 or the New Zealand statutory minimum, eliminating any expectation of annual bonuses, and securing a waiver of related claims. Additionally, Mr. Beck forfeited all 392,155 unvested RSUs to redirect capital toward company priorities and strategic R&D initiatives, emphasizing long-term shareholder value over short-term incentives.

• ·Amendment approved by the Compensation Committee of the Board of Directors.
• ·Changes do not trigger Good Reason under the Company’s Executive Severance Plan.

30-03-2026

Invech Holdings, Inc. (IVHI) filed an 8-K on March 30, 2026, disclosing the adoption of Amended and Restated Bylaws effective March 27, 2026, under Items 1.01, 5.03, and 9.01. The bylaws establish the principal office in Nevada, govern stock certificates (including uncertificated shares), transfers, stockholder meetings (annual and special), quorum at one-third (1/3) of voting power, notice periods (10-60 days), and proxy validity (6 months). No financial metrics, operational changes, or performance data are mentioned.

• ·Stockholder meeting quorum: one-third (1/3) of voting power present in person or by proxy
• ·Meeting notice: not less than 10 days nor more than 60 days prior
• ·Proxy validity: not more than 6 months from execution
• ·Stock transfer books may be closed for up to 60 days; record date not more than 60 or less than 10 days prior to action

30-03-2026

Teladoc Health (NYSE: TDOC) appointed Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors effective March 30, 2026, following the retirements of directors Eric Evans and Thomas McKinley and the recent appointment of Michael Smith. Ms. Salka, who during her 33-year tenure at AMN drove 26 acquisitions and grew revenue to over $5 billion, will serve on the board's audit and compensation committees. Chairman Kenneth H. Paulus highlighted her healthcare leadership and governance experience to support Teladoc's care delivery transformation.

• ·Susan Salka holds an MBA in Finance from San Diego State University and a BA in Accounting and Economics from Chadron State College.
• ·Investor contact: Michael Minchak (IR@teladochealth.com, 617-444-9612).
• ·Media contact: Lou Serio (PR@teladochealth.com, 202-569-9715).

30-03-2026

On March 25, 2026, SunPower Inc. held a Special Meeting of Stockholders, approving all six proposals, including the Second Amendment to the 2023 Equity Incentive Plan increasing shares reserved for issuance to 44,573,109. Stockholders also approved share issuances related to prior acquisitions, an additional $22,225,000 of 7.00% Convertible Senior Notes due 2029, increasing the White Lion Purchase Agreement commitment from $30.0 million to $55.0 million, and the Yorkville Standby Equity Purchase Agreement, with strong support across proposals (over 66 million votes for each). However, opposition was notable on Proposal 3 (3.05 million against), Proposal 5 (1.25 million against), and Proposal 6 (8.44 million against).

• ·Proposal 1 approved issuance of shares in excess of 3,333,334 related to September 21, 2025 Membership Interest Purchase Agreement.
• ·Proposal 2 approved shares issuable upon conversion of additional $22,225,000 7.00% Notes.
• ·Proposal 3 approved post-closing consideration shares in excess of 16,620,910 related to November 21, 2025 Membership Interest Purchase Agreement.
• ·Proposal 4 approved increase of White Lion commitment from $30.0 million to $55.0 million.
• ·Proposal 5 approved shares under Yorkville Purchase Agreement potentially exceeding 20% of outstanding Common Stock as of January 27, 2026.

30-03-2026

On March 24, 2026, the Compensation Committee of Assembly Biosciences, Inc. approved the 2026 Corporate Bonus Plan, effective January 1, 2026, to provide cash bonuses based on corporate and individual performance objectives for eligible employees, including named executive officers. Bonus targets are set at up to 75% of base salary for the CEO, 30%-55% for other executive participants, and up to 28% for non-executive participants, with payouts ranging from 0% to 150% of target and requiring employment through the payment date in the first quarter following the performance period. Separately, CEO Jason A. Okazaki's bonus target was increased from 60% to 65% of his base salary for fiscal year 2026.

• ·Corporate Objectives weighted 100% for CEO, 75% for C-Level/SVP/VP (with 25% individual), 50% for Director-level (50% individual), and 25% for Associate Director and below (75% individual).
• ·Corporate Objectives approved by Board within 90 days of Performance Period start; adjustable for unanticipated events.
• ·Exhibits include full 2026 Corporate Bonus Plan (10.1) and Amendment No. 1 to Okazaki's employment agreement (10.2).

30-03-2026

On March 25, 2026, Steven I-Fang Cheng resigned as a member of the Board of Directors and Chief Technology Officer of Advanced Biomed Inc., with the resignation not due to any disagreement on operations, policies, or practices. On the same date, the Board appointed Mingze Yin, the Company's Chief Financial Officer, as a new Director. There are no family relationships, arrangements, or disclosable transactions involving Mr. Yin under Item 404(a) of Regulation S-K.

• ·Filing date: March 30, 2026; Earliest event date: March 25, 2026
• ·Company CIK: 0001941029; EIN: 87-2177170; Incorporated in Nevada; Fiscal year end: June 30
• ·Principal executive offices: No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan; Phone: 886-6-3121716
• ·Emerging growth company: Yes; Common Stock (ADVB) registered on Nasdaq

30-03-2026

Inogen, Inc. announced leadership appointments to accelerate growth, including Jason Richardson as CFO effective April 6, 2026, succeeding Michael Bourque who will advise until June 30, 2026; Dominic Hulton as CMO effective April 1, 2026; and Corey Moritz as VP U.S. B2B Sales since March 9, 2026. These executives bring extensive experience from Baxter International ($3B segment), Insulet, and Rhythm Healthcare, with Bourque credited for achieving positive adjusted EBITDA for the first time in four years. The company reaffirmed its Q1 and FY 2026 financial outlook previously issued on February 24, 2026.

• ·Dominic Hulton has over 20 years of experience, including 11 years at Insulet.
• ·Corey Moritz has more than two decades of experience and built six sales forces.
• ·Forward-looking statements subject to risks detailed in 10-K for period ended December 31, 2025.

30-03-2026

On March 24, 2026, the Compensation Committee of Graham Corporation's Board of Directors approved annual base salary increases for President and CEO Matthew J. Malone to $600,000 and for VP-Finance, CFO, and Chief Accounting Officer Christopher J. Thome to $400,000. The Committee also increased Malone's target LTIP award for fiscal 2027 to 200% of his base salary and Thome's target Executive Cash Bonus Program award to 70% of his base salary. No other changes to officer positions or departures were reported.

• ·Compensation Committee approvals effective March 24, 2026
• ·Form 8-K filed March 30, 2026

30-03-2026

On March 25, 2026, the Board of Directors of The LGL Group, Inc. approved a modification to the compensatory arrangement for Chief Executive Officer Jason Lamb, effective January 5, 2026, entitling him to an annual base salary of $190,000. This salary is in addition to the previously disclosed $60,000 incentive draw. No other changes were made to Mr. Lamb's compensation arrangements.

• ·Form 8-K filed on March 30, 2026, reporting event dated March 25, 2026.
• ·Previous disclosure in Amendment No. 1 to Form 8-K filed January 9, 2026.

30-03-2026

On March 26, 2026, the Board of Directors of WEBTOON Entertainment Inc. approved a Housing Assistance Policy for the company's Chief Executive Officer in connection with the CEO's relocation from Korea to the United States for business purposes. The policy provides a fixed annual cash allowance of $250,350, paid on a monthly basis, with eligibility requiring active employment at the time of payment. The full text of the policy is filed as Exhibit 10.1 to this Form 8-K.

• ·Policy approved for CEO relocation of primary residence from Korea to the United States
• ·Housing Assistance Policy filed as Exhibit 10.1

30-03-2026

Apollo Global Management, Inc. issued $750,000,000 aggregate principal amount of 5.700% Senior Notes due 2036 on March 30, 2026, pursuant to an indenture with U.S. Bank Trust Company, National Association as trustee. The proceeds will be used for general corporate purposes, including the repurchase or repayment of $500,000,000 outstanding 4.400% Senior Notes due 2026 issued by Apollo Management Holdings, L.P. Interest on the new notes accrues at 5.700% per annum, payable semi-annually starting September 30, 2026, with maturity on March 30, 2036.

• ·Underwriting agreement dated March 25, 2026, with BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC as representatives.
• ·Indenture dated March 30, 2026; notes sold pursuant to Form S-3 registration statement (File No. 333-271275).
• ·Opinion of counsel from Paul, Weiss, Rifkind, Wharton & Garrison LLP filed as Exhibit 5.1.

30-03-2026

DarioHealth Corp. entered into a Sales Agreement with A.G.P./Alliance Global Partners on March 30, 2026, enabling the potential issuance and sale of up to $20,000,000 of common stock via an at-the-market offering program. Net proceeds may fund commercial and marketing activities, R&D, M&A, repayment of debt to Callodine Commercial Finance, LLC, and general working capital. The Agent earns a 3.00% commission on gross proceeds, with reimbursements capped at $35,000 initially plus additional quarterly and refresh fees.

• ·Sales Agreement uses effective Form S-3 shelf registration (File No. 333-294454), filed March 19, 2026, effective March 27, 2026.
• ·Offering terminates upon full share sales, registration expiration, or party termination.
• ·Common stock: par value $0.0001 per share, traded as DRIO on Nasdaq Capital Market.

30-03-2026

WisdomTree, Inc. issued $603.75 million in aggregate principal amount of 4.50% Convertible Senior Notes due 2031 pursuant to an Indenture dated March 30, 2026, generating approximately $591.2 million in net proceeds from the private offering to qualified institutional buyers. The notes are senior unsecured obligations ranking equal to the company's existing convertible notes due 2026, 2029, and 2030, with interest payable semiannually at 4.50% and maturity on October 1, 2031. Holders may convert under specified conditions at an initial rate of 46.3306 shares per $1,000 principal (approximately $21.58 per share), with no early redemption before April 6, 2028.

• ·Initial conversion rate: 46.3306 shares per $1,000 principal amount (approx. $21.58 per share); maximum conversion rate: 74.1282 shares per $1,000.
• ·Notes not redeemable before April 6, 2028; interest payments begin October 1, 2026.
• ·Purchase Agreement dated March 23, 2026.

30-03-2026

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced an oversubscribed $30 million private placement financing led by Soleus Capital, with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and insiders, expected to close on or about March 31, 2026. The offering includes pre-funded warrants and warrants to purchase approximately 37.2 million shares of common stock each, with gross proceeds intended for general corporate purposes, R&D, and expanding the ACESOT-1051 Phase 1 trial enrollment in uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) patients. The proceeds are expected to extend the company's cash runway into Q1 2028, with dose escalation completion anticipated in Q2 2027.

• ·Warrants exercisable immediately upon issuance and expire on the earlier of December 31, 2029, or 30 days after pro rata exercise of corresponding Pre-Funded Warrant
• ·Company to file SEC registration statement for resale of securities
• ·Oppenheimer & Co. Inc. acting as lead placement agent; Maxim Group LLC as co-lead

30-03-2026

On March 26, 2026, Universal Health Services, Inc.'s Compensation Committee approved 2026 annual incentive bonus formulae for executive officers under the 2022 Executive Incentive Plan, with targets at 150% of base salary for CEO Marc D. Miller and 100% for others, based on adjusted net income per diluted share and return on capital. A discretionary $1.07 million cash bonus was approved for Executive Chairman Alan B. Miller for 2025. The Committee also awarded time-based RSUs and performance-based PBRSUs to executives under the 2020 Omnibus Stock and Incentive Plan, computed at $185.09 per share.

• ·RSUs vest in four equal annual installments starting on first anniversary of March 26, 2026 grant date.
• ·PBRSUs based on three-year average (2026-2028) Adjusted EBITDA net of NCI; 50% payout at 90% threshold, 200% at 110%+ threshold.
• ·Annual incentives for Sim and Peterson: 25% corporate criteria (adjusted net income per diluted share and return on capital), 75% divisional pre-tax income net of capital cost.
• ·Corporate performance criteria exclude nonrecurring/non-operational items; divisional targets adjustable similarly.

30-03-2026

On March 30, 2026, Charging Robotics Inc. appointed Amir Nardimon, founder and CEO of Deliverz.ai Ltd., and Itay Meroz, director at Formula Systems (1985) Ltd., to its Board of Directors, effective immediately, bringing expertise in AI robotics, software engineering, and financial management. Concurrently, directors Amitay Weiss and Kineret Tzedef resigned for personal reasons, with no disagreements with the company or management. The new directors will receive standard non-executive compensation as detailed in the 2025 Form 10-K, with no related arrangements or disclosable transactions under Item 404(a).

30-03-2026

Reginald T. Jackson, Senior Vice President and Chief Accounting Officer of Entergy Corporation and its operating companies (Entergy Arkansas LLC, Entergy Louisiana LLC, Entergy Mississippi LLC, Entergy New Orleans LLC, and Entergy Texas Inc.), intends to retire effective May 31, 2026. Patrick J. Stack, age 53 and currently Corporate Controller of Entergy Services LLC, will be appointed to succeed him as Senior Vice President and Chief Accounting Officer starting June 1, 2026, with an annual base salary of $356,000 and eligibility for an annual incentive bonus targeted at 45% of base salary. There are no related arrangements, family relationships, or material related party transactions.

• ·Event reported on March 25, 2026; filing dated March 30, 2026.
• ·Mr. Stack held position of Controller, Utility Operations Accounting at Entergy Services LLC from January 2019 to March 2022.
• ·Compensation awards determined via normal annual review process consistent with seniority and responsibility.

30-03-2026

Genasys Inc. (NASDAQ: GNSS) appointed Larry Hagenbuch to its Board of Directors effective March 30, 2026, where he will serve as Chair of the Audit Committee. Mr. Hagenbuch, an operating partner at Crossplane Capital, brings extensive audit, financial oversight, operational, and restructuring experience from prior roles including audit chair at HireQuest (HQI) and Optex Systems, interim C-level positions at Huron Consulting, and positions at GE, GE Capital, and J. Hilburn. CEO Richard Danforth highlighted Hagenbuch's qualifications to support scaling growth amid opportunities like the Puerto Rico Dams Early Warning System project.

• ·Mr. Hagenbuch began career in U.S. Navy as weapons officer on USS Reuben James (FFG-57).
• ·Earned BS in Mechanical and Materials Engineering from Vanderbilt University and MBA from Wharton School at University of Pennsylvania.
• ·Genasys covers more than 155 million people in all 50 U.S. states and over 100 countries worldwide.
• ·References risks including Puerto Rico project funding uncertainties, geopolitical unrest, and need for additional capital in forward-looking statements.

30-03-2026

Compass Diversified (CODI) announced a definitive agreement to sell Sterno’s food service business to Archer Foodservice Partners for an enterprise value of $292.5 million, with the divested business generating $30.3 million in subsidiary adjusted EBITDA in 2025. Net proceeds will repay debt, reducing CODI's senior secured net leverage ratio below 1.0x and avoiding excess leverage fees beyond June 30, 2026. CODI will retain the higher-margin Rimports home fragrance business, which reported $28.1 million adjusted EBITDA in 2025.

• ·Transaction expected to close in May 2026, subject to customary closing conditions including regulatory approvals.
• ·Raymond James served as financial advisor to CODI; Brownstein Hyatt Farber Schreck, LLP as legal counsel.
• ·Sterno’s brand roots date back over 125 years.

30-03-2026

On March 26, 2026, Unnikrishnan (Unni) Balakrishnan Nambiar resigned as Chief Technology Officer of Aeries Technology, Inc., effective March 31, 2026, to assume a leadership role at the Company's wholly-owned Indian subsidiary, Aeries Technology Group Business Accelerators Private Limited. The Board of Directors appointed Bhisham (Ajay) Khare, the current Chief Executive Officer, Principal Financial Officer, and Director, as Principal Accounting Officer, effective March 31, 2026. No material compensatory arrangements, family relationships, or disclosable transactions under Item 404(a) were entered into with Mr. Khare.

• ·Bhisham (Ajay) Khare, age 48, has served as CEO and Director since February 2025, and Chief Revenue Officer and COO since November 2023 business combination.
• ·Prior to business combination, Mr. Khare was Chief Revenue Officer and COO for the Americas division of Aeries group since 2015.
• ·No family relationships between Mr. Khare and any current or former directors or executive officers.

30-03-2026

Rapid7, Inc. entered into a Nomination and Support Agreement with JANA Partners Management, LP on March 26, 2026, agreeing to nominate and support Kevin Galligan for election as a director at the 2026 annual meeting of stockholders on the same terms as other board nominees. JANA committed to voting its shares in favor of Galligan and the Company's specified directors (Corey E. Thomas, Marc Brown, Judy Bruner, Mike Burns, Benjamin Holzman, Wael Mohamed, J. Benjamin Nye, Thomas Schodorf, Reeny Sondhi) at the meeting. The agreement caps JANA's ownership at 19.9% without board consent and terminates on the earlier of 30 days prior to the 2027 director nomination advance notice period or January 8, 2027.

• ·Board approved JANA's acquisitions up to 19.9% ownership threshold to waive Delaware General Corporation Law Section 203 business combination restrictions.
• ·Agreement filed as Exhibit 10.1.

30-03-2026

Tenet Healthcare Corporation extended the retirement date of Senior Vice President & Controller (Principal Accounting Officer) R. Scott Ramsey to April 30, 2026, from March 31, 2026, with part-time transition services through March 31, 2028. The Company appointed J. Michael Grooms, age 48 and former Senior Vice President, Chief Accounting Officer at Lifepoint Health, Inc., as Senior Vice President & Controller effective April 6, 2026, succeeding Ramsey as Principal Accounting Officer on May 1, 2026. Grooms' compensation includes an annual base salary of $475,000, target cash bonus at 60% of salary, initial RSUs with $500,000 grant date value, a $250,000 sign-on bonus, and relocation benefits.

• ·Mr. Grooms' initial RSUs vest one-half on the second anniversary of the grant date and the other half on the third anniversary.
• ·Recommended 2027 equity award for Mr. Grooms comprised of 50% service-based RSUs and 50% performance-based RSUs.
• ·Event reported on March 25, 2026; filing dated March 30, 2026.